早期化疗强化:两周期ABVD后PET/CT阳性的晚期霍奇金淋巴瘤患者接受 escalated BEACOPP 治疗的长期结果:GITIL/FIL HD 0607 试验
该研究纳入782例晚期霍奇金淋巴瘤患者,两周期ABVD后行PET2评估,阳性者随机接受 escalated BEACOPP 联合或不联合利妥昔单抗,阴性者继续ABVD。PET2阳性组3年PFS为60%,阴性组为87%(P<.001);阳性组中联合利妥昔单抗与否3年PFS为63% vs 57%(P=.53)。结论认为PET驱动的ABVD转换为 escalated BEACOPP 在高危晚期HL中可行且有效。
要点
- 两周期ABVD后PET2阳性晚期霍奇金淋巴瘤患者3年PFS为60%,阴性者为87%(P<.001)。
- PET2阳性患者接受 escalated BEACOPP 联合或不联合利妥昔单抗的3年PFS为63% vs 57%(P=.53)。
- 诊断时有大肿块且化疗后PET阴性的患者随机加放疗未显著改善PFS(97% vs 93%,P=.29)。
核心结论
- PET驱动的从ABVD转换为 escalated BEACOPP 在高危晚期霍奇金淋巴瘤患者中可行且有效。
研究设计与样本
- 前瞻性随机试验,连续纳入782例晚期(IIB至IVB)霍奇金淋巴瘤患者,两周期ABVD后行PET2中央评审(Deauville五分法)。
- PET2阳性者随机接受4周期 escalated BEACOPP 后4周期标准BEACOPP联合或不联合利妥昔单抗。
- PET2阴性者继续ABVD;诊断时有大肿块(≥5 cm)且化疗结束PET阴性并完全缓解者随机接受放疗或不进一步治疗。
- 主要终点为3年无进展生存(PFS)。
主要发现
- 782例中150例(19%)PET2阳性,630例(81%)阴性。
- 全部患者3年PFS为82%;PET2阳性组3年PFS为60%,阴性组为87%(P<.001)。
- PET2阳性患者接受 escalated BEACOPP 联合利妥昔单抗组3年PFS为63%,不联合利妥昔单抗组为57%(P=.53)。
- 296例中期及ABVD后PET均阴性且诊断时有大肿块的患者中,化疗后随机加放疗组3年PFS为97%,不加放疗组为93%(P=.29)。
- 全部782例患者3年总生存为97%;PET2阴性组为99%,阳性组为89%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive positron emission tomography scan performed after two doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) cycles (PET2). Patients and Methods Patients with advanced-stage (IIB to IVB) HL were consecutively enrolled. After two ABVD cycles, PET2 was performed and centrally reviewed according to the Deauville five-point scale. Patients with a positive PET2 were randomly assigned to four cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) followed by four cycles of standard BEACOPP with or without rituximab. Patients with a negative PET2 continued ABVD, and those with a large nodal mass at diagnosis (≥ 5 cm) in complete remission with a negative PET at the end of chemotherapy were randomly assigned to radiotherapy or no further treatment. The primary end point was 3-year PFS. Results Of 782 enrolled patients, 150 (19%) had a positive and 630 (81%) a negative PET2. The 3-year PFS of all patients was 82%. The 3-year PFS of those with a positive and negative PET2 was 60% and 87%, respectively ( P < .001). The 3-year PFS of patients with a positive PET2 assigned to BEACOPP with or without rituximab was 63% versus 57% ( P = .53). In 296 patients with both interim and post-ABVD-negative PET who had a large nodal mass at diagnosis, radiotherapy was randomly added after chemotherapy without a significant PFS improvement (97% v 93%, respectively; P = .29). The 3-year overall survival of all 782 patients was 97% (99% and 89% for PET2 negative and positive, respectively). Conclusion The PET-driven switch from ABVD to escalated BEACOPP is feasible and effective in high-risk patients with advanced-stage HL.
引用
- Gallamini A, Tarella C, Viviani S, et al. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. J Clin Oncol. 2018. PMID: 29360414. doi:10.1200/JCO.2017.75.2543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。